2,5-dimethyl Celecoxib

Confirm delete?

Zoom

Cat No: 10008006

Biochemicals - Small Molecule Inhibitors

2,5-dimethyl Celecoxib is a derivative of celecoxib (Item No. 10008672) that does not inhibit COX-2 (IC50 = >100 µM).{45305} It does inhibit microsomal prostaglandin E synthase-1 (mPGES-1) in HeLa cells (IC50 = 15.6 µM) and reduces prostaglandin E2 (P...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

4-[5-(2,5-dimethylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-benzenesulfonamide

Correlated keywords:

Dimethylcelecoxib anti-cancer COX2 mPGES1 E-2 PGE-2 A-549 HCA7 RPMI-8226 Dox-40 MEK-1 proliferative

Product Overview:
2,5-dimethyl Celecoxib is a derivative of celecoxib (Item No. 10008672) that does not inhibit COX-2 (IC50 = >100 µM).{45305} It does inhibit microsomal prostaglandin E synthase-1 (mPGES-1) in HeLa cells (IC50 = 15.6 µM) and reduces prostaglandin E2 (PGE2; Item No. 14010) production in HeLa, A549, and HCA-7 cells (IC50s = 0.64, 0.83, and 3.08 µM, respectively).{45306} It inhibits proliferation of drug-sensitive RPMI8226 and multidrug-resistant 8226/Dox40 multiple myeloma cells, as well as increases the rate of apoptosis when used at concentrations of 20 and 30 µM.{45307} 2,5-dimethyl Celecoxib reduces the expression of survivin, cyclin A, cyclin B, MEK1, and MEK2 in 8226/Dox40 cells. The antiproliferative effect of 2,5-dimethyl celecoxib is independent of mPGES-1 inhibition.{45306}

Size	5 mg
Shipping	dry ice
CAS Number	457639-26-8
Molecular Formula	C₁₈H₁₆F₃N₃O₂S
SMILES	O=S(C(C=C1)=CC=C1N2N=C(C(F)(F)F)C=C2C3=CC(C)=CC=C3C)(N)=O
Molecular Weight	395,4
Formulation	A solid
Purity	≥95%
Custom Code	2935.90
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.